Scientists at St. Jude Children’s Research Hospital, alongside collaborators around the world, have created a comprehensive reference of functional variants in an important drug-metabolizing enzyme called NUDT15. This thorough understanding of NUDT15 variants provides an invaluable resource for predicting which patients being treated with thiopurine drugs for acute lymphoblastic leukemia (ALL) are likely to experience toxicity. The work was published today in Proceedings of the National Academy of Science.
Thiopurines are important antimetabolite drugs, which make up a critical part of curative treatment for ALL. Genetic variations can directly influence drug toxicity and effectiveness of thiopurines. Researchers at St. Jude and elsewhere previously identified NUDT15 variants as a major genetic cause of toxicity during thiopurine therapy, particularly in people of Asian and Hispanic descent.
Pharmacogenetics is a field of science that uses genomic data to guide precision medicine. To implement genetic-guided treatment, researchers need a rigorous and thorough understanding of all the variants and their functions. The vast majority of genetic variants in the human genome remain uncharacterized. These variants are considered of unknown significance, leaving a void in our knowledge about how to implement precision medicine, including pharmacogenetics, for these patients.
“To address this issue, we designed a high throughput experimental system to characterize the functional consequences of 91% of all possible genetic variants of the NUDT15 gene,” said senior author Jun J. Yang, Ph.D., of the St. Jude Departments of Pharmaceutical Sciences and Oncology. “In the span of only a few months, we experimentally studied close to 3,000 variants in this gene in parallel and found that 30% are damaging, which we predicted to cause thiopurine toxicity in patients.”
Variants identified in this way (by function) more accurately predict toxicity in patients treated with thiopurines than bioinformatic algorithms can. Using patient data with a subset of these variants, the researchers found that NUDT15 variants predicted by this method to cause toxicity, did induce such toxicity. Conversely, the variants predicted to have benign effects did not cause toxicity. While the authors caution that future studies of larger sample sizes are needed to validate these results, the initial findings show promise.
“This reference vastly improves the ability to implement pharmacogenetics-guided thiopurine treatment, not just for ALL but for other diseases treated with thiopurines such as inflammatory bowel disease,” said first author Chase Suiter, formerly of St. Jude and now a graduate student at the University of Washington. “Importantly, the scale of this type of variant-scanning experiment was almost unimaginable just a couple of years ago, and we are excited about applying it to study many other genes related to drug response.”
Other St. Jude authors are Takaya Moriyama, Wentao Yang, Rina Nishii, Wenjian Yang, Keito Hoshitsuki, Chris Parish, Colton Smith, Lie Li and Mary Relling. Additional authors include Kenneth Matreyek and Douglas Fowler of the University of Washington; Emma Rose Scaletti and Pal Stenmark of Stockholm University; Minu Singh, Amita Trehan and Prateek Bhatia of PGIMER; Deepa Bhojwani of Children’s Hospital of Los Angeles; Liz YP Yuen of Hong Kong Children’s Hospital; Chi-kong Li of the Chinese University of Hong Kong; Chak-ho Li of Tuen Mun Hospital Hong Kong; Yung-li Yang of National Taiwan University; Gareth Walker, James Goodhand, Nicholas Kennedy and Tariq Ahmad of the University of Exeter; Federico Antillon Klussman of Unidad Nacional de Oncologia Pediatrica Guatemala; Smita Bhatia of the University of Alabama at Birmingham; Motohiro Kato of the National Center for Child Health and Development Tokyo; Hiroki Hori of the Mie University Graduate School of Medicine; and Allen Yeoh of the National University of Singapore.
The research at St. Jude was funded in part by the National Institutes of Health (CA021765, GM115279, GM118578, R01CA096670, U10CA098543, U10CA098413, U10CA095861, U10CA180886 and U10CA180899), the V Foundation for Cancer Research, Alex’s Lemonade Stand Foundation and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.